Evaluation of the Impact of Food on the Pharmacokinetics of CA-4948 in Healthy Male Subjects with Hematologic Malignancies

The primary objective of this study is to evaluate the effect of food on the **pharmacokinetics** of CA-4948 in healthy male subjects. Understanding the impact of food intake on the absorption, distribution, metabolism, and excretion of CA-4948 is clinically relevant as it may influence dosing recommendations and therapeutic efficacy in patients with **hematologic malignancies**. No secondary objectives are provided for this study.

The clinical trial focuses on **hematologic malignancies** and involves a study population exclusively composed of male participants. The age range of the participants is categorized as adults, specifically those aged 18 years and older. The trial does not include vulnerable populations. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the effect of food on the pharmacokinetics of CA-4948 in healthy male subjects. This study is a **Phase 3** trial, focusing on individuals with **hematologic malignancies**. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is January 19, 2024, with an anticipated end date of April 2, 2024, indicating a total trial duration of approximately three months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion in the trial. Following the screening, participants will be randomly assigned to either the treatment or control group, maintaining the double-blind nature of the study. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, adherence to the study protocol, and any potential adverse effects. These visits are crucial for collecting data on the pharmacokinetics of CA-4948 under different dietary conditions.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the study's primary and secondary endpoints. The expected length of participant involvement is approximately three months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to ensure the safety and well-being of participants while providing valuable insights into the pharmacokinetics of CA-4948.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 19, 2024, with an estimated end date of April 2, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 3 study, which generally aims to confirm the effectiveness of a treatment in a larger patient population. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.